Holen Sie sich die Stockscreener-App
0.874
4.05%
0.034
Handel nachbörslich:
.99
0.116
+13.27%
Schlusskurs vom Vortag:
$0.84
Offen:
$0.841
24-Stunden-Volumen:
21,138
Relative Volume:
0.12
Marktkapitalisierung:
$31.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.53M
KGV:
-3.5908
EPS:
-0.2434
Netto-Cashflow:
$-12.75M
1W Leistung:
+2.71%
1M Leistung:
-11.72%
6M Leistung:
-23.33%
1J Leistung:
-40.95%
1-Tages-Spanne:
$0.84
$0.9229
1-Wochen-Bereich:
$0.8201
$0.9229
52-Wochen-Spanne:
$0.63
$3.23
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Firmenname
Estrella Immunopharma Inc
Sektor
Branche
Telefon
(510) 318-9098
Adresse
5858 HORTON STREET, SUITE 370, EMERYVILLE
Vergleichen Sie ESLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
0.874 | 30.77M | 0 | -8.53M | -12.75M | -0.2434 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten
What analysts say about Estrella Immunopharma Inc. stockMarket-leading growth rates - jammulinksnews.com
Estrella Immunopharma Inc. Stock Analysis and ForecastFree Stock Market Return Analysis - jammulinksnews.com
How Estrella Immunopharma Inc. stock performs during market volatilityHigh Yield Stock Selection - Newser
What drives Estrella Immunopharma Inc. stock priceExponentially increasing returns - Autocar Professional
Is Estrella Immunopharma Inc. a good long term investmentMarket-beating performance - Autocar Professional
how estrella immunopharma inc. stock performs during market volatilityCapital Efficient Investment Tips - Newser
Is Estrella Immunopharma Inc. stock overhyped or has real potentialSolid Return Trade Selections - Newser
What makes Estrella Immunopharma Inc. stock price move sharplyTop Growth Low Risk Stocks - Newser
Why Estrella Immunopharma Inc. stock attracts strong analyst attentionLong Term Low Risk Growth - Newser
Estrella Immunopharma Expands STARLIGHT-1 Trial with New Texas Clinical Site - MSN
Estrella Immunopharma opens new trial site for cancer therapy By Investing.com - Investing.com South Africa
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II Starlight-1 Trial in B-Cell Non-Hodgkin's Lymphoma - MarketScreener
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma - BioSpace
Estrella Immunopharma (ESLA) Expands Clinical Trial with New Sit - GuruFocus
Estrella Immunopharma opens new trial site for cancer therapy - Investing.com Australia
Estrella Immunopharma Expands STARLIGHT-1 Clinical Trial - TipRanks
Estrella Immunopharma Announces Activation Of Additional Site For Phase I/Ii Starlight-1 Trial In B-Cell Non-Hodgkin'S Lymphoma - marketscreener.com
Estrella Immunopharma secures $3.35M in financing to advance clinical triall; shares up - MSN
Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | E - GuruFocus
Estrella Immunopharma secures $3.35 million in PIPE financing By Investing.com - Investing.com South Africa
Analyst Maintains Buy Rating on Estrella Immunopharma (ESLA) | ESLA Stock News - GuruFocus
Estrella Immunopharma (ESLA) Secures $3.35M Through Private Equi - GuruFocus
Estrella Immunopharma secures $3.35 million in PIPE financing - Investing.com Australia
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing - Business Wire
Estrella Immunopharma’s (ESLA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial - Yahoo
ESLA Stock Rating and Price Target Maintained by D. Boral Capita - GuruFocus
Finanzdaten der Estrella Immunopharma Inc-Aktie (ESLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):